摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(azetidine-1-carbonyl)-2-methyl-2H-pyrazole-3-carboxylic acid (2-bromo-[1,2,4]triazolo[1,5-a]pyridin-7-yl)amide | 1380330-43-7

中文名称
——
中文别名
——
英文名称
4-(azetidine-1-carbonyl)-2-methyl-2H-pyrazole-3-carboxylic acid (2-bromo-[1,2,4]triazolo[1,5-a]pyridin-7-yl)amide
英文别名
4-(azetidine-1-carbonyl)-N-(2-bromo-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-1-methyl-1H-pyrazole-5-carboxamide;4-(azetidine-1-carbonyl)-N-(2-bromo-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methylpyrazole-3-carboxamide
4-(azetidine-1-carbonyl)-2-methyl-2H-pyrazole-3-carboxylic acid (2-bromo-[1,2,4]triazolo[1,5-a]pyridin-7-yl)amide化学式
CAS
1380330-43-7
化学式
C15H14BrN7O2
mdl
——
分子量
404.226
InChiKey
XUPXSKZXYSGJCI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.8
  • 重原子数:
    25
  • 可旋转键数:
    3
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.27
  • 拓扑面积:
    97.4
  • 氢给体数:
    1
  • 氢受体数:
    5

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] TRIAZOLOPYRIDINE COMPOUNDS<br/>[FR] COMPOSÉS DE TRIAZOLOPYRIDINE
    申请人:HOFFMANN LA ROCHE
    公开号:WO2012076430A1
    公开(公告)日:2012-06-14
    The invention is concerned with triazolopyridine compounds of formula (I), wherein R1, R2 , R3 and R4 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit PDEIOA and can be used as medicaments.
    本发明涉及通式(I)的三唑并吡啶化合物,其中R1、R2、R3和R4如说明书和权利要求中所定义,以及其生理上可接受的盐。这些化合物抑制PDEIOA,可用作药物。
  • [EN] Pd-CATALYZED COUPLING OF PYRAZOLE AMIDES<br/>[FR] COUPLAGE DE PYRAZOLE-AMIDES CATALYSÉ PAR PD
    申请人:HOFFMANN LA ROCHE
    公开号:WO2014177493A1
    公开(公告)日:2014-11-06
    A novel process for the preparation of imidazo[1,2-a]pyridine compounds of the formula (I), wherein R1 is C1-4-alkoxy or NR4R5 wherein R4 and R5 are independently hydrogen or C1-4-alkyl or R4 and R5, together with the nitrogen atom to which they are attached, form a saturated 4- to 6-membered heterocyclic ring which may contain one further heteroatom selected from nitrogen or oxygen; R2 is C1-4-alkyl, C1-4-alkoxycarbonyl, halogen, phenyl which is optionally substituted with C1-4-alkyl, C1-4-alkoxy or halogen or is NR4R5 wherein R4 and R5 are independently hydrogen or C1-4-alkyl or R4 and R5, together with the nitrogen atom to which they are attached, form a saturated 4- to 6-membered heterocyclic ring which may contain one further heteroatom selected from nitrogen or oxygen; R3 is C1-4-alkyl and X is nitrogen or CH is described. The imidazo[1,2-a]pyridine compounds of the formula (I) are either precursors for active principles or active principles itself, acting as phosphodiesterase (PDE) inhibitors, particularly PDE10 inhibitors which have the potential to treat psychotic disorders like schizophrenia (Int. Patent Publication WO 2012/076430).
    一种制备式(I)的咪唑并[1,2-a]吡啶化合物的新工艺,其中R1为C1-4-烷氧基或NR4R5,其中R4和R5独立地为氢或C1-4-烷基,或R4和R5与它们所连接的氮原子一起形成一个饱和的4-至6-成员杂环环,该环可包含一种进一步从氮或氧中选择的杂原子;R2为C1-4-烷基,C1-4-烷氧羰基,卤素,苯,可选地被C1-4-烷基,C1-4-烷氧基或卤素取代或为NR4R5,其中R4和R5独立地为氢或C1-4-烷基,或R4和R5与它们所连接的氮原子一起形成一个饱和的4-至6-成员杂环环,该环可包含一种进一步从氮或氧中选择的杂原子;R3为C1-4-烷基,X为氮或CH。式(I)的咪唑并[1,2-a]吡啶化合物是活性原料或活性原料本身,作为磷酸二酯酶(PDE)抑制剂,特别是PDE10抑制剂,具有治疗精神分裂症等精神障碍的潜力(国际专利出版物WO 2012/076430)。
  • Pd-CATALYZED COUPLING OF PYRAZOLE AMIDES
    申请人:HOFFMANN-LA ROCHE INC.
    公开号:US20160046628A1
    公开(公告)日:2016-02-18
    A novel process for the preparation of imidazo[1,2-a]pyridine compounds of the formula wherein R 1 is C 1-4 -alkoxy or NR 4 R 5 wherein R 4 and R 5 are independently hydrogen or C 1-4 -alkyl or R 4 and R 5 , together with the nitrogen atom to which they are attached, form a saturated 4- to 6-membered heterocyclic ring which may contain one further heteroatom selected from nitrogen or oxygen; R 2 is C 1-4 -alkyl, C 1-4 -alkoxycarbonyl, halogen, phenyl which is optionally substituted with C 1-4 -alkyl, C 1-4 -alkoxy or halogen or is NR 4 R 5 wherein R 4 and R 5 are independently hydrogen or C 1-4 -alkyl or R 4 and R 5 , together with the nitrogen atom to which they are attached, form a saturated 4- to 6-membered heterocyclic ring which may contain one further heteroatom selected from nitrogen or oxygen; R 3 is C 1-4 -alkyl and X is nitrogen or CH is described. The imidazo[1,2-a]pyridine compounds of the formula I are either precursors for active principles or active principles itself, acting as phosphodiesterase (PDE) inhibitors, particularly PDE10 inhibitors which have the potential to treat psychotic disorders like schizophrenia (Int. Patent Publication WO 2012/076430).
    一种制备式为R1为C1-4-烷氧基或NR4R5,其中R4和R5分别是氢或C1-4-烷基或R4和R5连同它们所连接的氮原子形成饱和的4-至6-成员杂环环,该环可能含有一种进一步的杂原子,所选自氮或氧的咪唑并[1,2-a]吡啶化合物的新方法;其中R2为C1-4-烷基,C1-4-烷氧羰基,卤素,苯基,该苯基可以选择性地被C1-4-烷基,C1-4-烷氧基或卤素取代或是NR4R5,其中R4和R5分别是氢或C1-4-烷基或R4和R5连同它们所连接的氮原子形成饱和的4-至6-成员杂环环,该环可能含有一种进一步的杂原子,所选自氮或氧;R3为C1-4-烷基,X为氮或CH,本文描述了式I的咪唑并[1,2-a]吡啶化合物。式I的咪唑并[1,2-a]吡啶化合物是活性原料的前体或活性原料本身,作为磷酸二酯酶(PDE)抑制剂,特别是PDE10抑制剂,具有治疗精神分裂症等精神障碍的潜力(国际专利出版物WO 2012/076430)。
  • Palladium-Catalyzed C–N Coupling of Pyrazole Amides with Triazolo- and Imidazopyridine Bromides in Ethanol
    作者:Fritz Bliss、Serena Fantasia、Erwann Le Coz、Kurt Püntener
    DOI:10.1021/acs.oprd.0c00437
    日期:2021.3.19
  • PALLADIUM-CATALYZED COUPLING OF PYRAZOLE AMIDES
    申请人:F. Hoffmann-La Roche AG
    公开号:EP2991984B1
    公开(公告)日:2017-03-08
查看更多

同类化合物

苯甲醇,2-甲基-a-[1-(甲基氨基)环戊基]- 溴-6-甲基[1,2,4]噻唑并[1,5-a]吡啶 乙基[1,2,4]三唑并[1,5-a]吡啶-2-羧酸酯 三(二甲基氨基)(3H-1,2,3-三唑[4,5-b]吡啶-3-基氧代)膦六氟磷酸盐 [1,2,4]噻唑并[4,3-a]吡啶-3-羧酸 [1,2,4]噻唑并[1,5-a]吡啶-8-胺 [1,2,4]噻唑并[1,5-a]吡啶-6-羧酸甲酯 [1,2,4]噻唑并[1,5-a]吡啶-6-羧酸 [1,2,4]噻唑并[1,5-a]吡啶-6-甲腈 [1,2,4]噻唑并[1,5-a]吡啶-6-甲胺 [1,2,4]噻唑并[1,5-a]吡啶-5-羧醛 [1,2,4]噻唑并[1,5-a]吡啶-5-羧酸甲酯 [1,2,4]噻唑并[1,5-a]吡啶-2-羧醛 [1,2,4]三氮唑[1,5-A]吡啶-6-甲醛 [1,2,4]三唑并[4,5-a]吡啶-3-磺酰胺 [1,2,4]三唑并[4,3-a]吡啶-5-羧酸 [1,2,4]三唑并[4,3-a]吡啶-5-硫醇 [1,2,4]三唑并[4,3-A]吡啶-8-胺 [1,2,4]三唑并[4,3-A]吡啶-7-羧酸 [1,2,4]三唑并[1,5-a]吡啶-7-羧酸 [1,2,4]三唑并[1,5-a]吡啶-6-胺 [1,2,4]三唑并[1,5-a]吡啶-5-羧酸 [1,2,4]三唑并[1,5-a]吡啶 [1,2,4]三唑并[1,5-A]吡啶-7-羧酸甲酯 [1,2,4]三唑并[1,5-A]吡啶-7-硼酸 [1,2,4]三唑[4,3-A]嘧啶-6-羧酸 [1,2,4]三唑[4,3-A]吡啶-3-硫醇 [1,2,4]三唑[1,5-a]吡啶-2-甲酸 [1,2,3]三唑并[1,5-a]吡啶-7-甲醛 [1,2,3]三唑并[1,5-a]吡啶-7-甲酰胺 [1,2,3]三唑并[1,5-a]吡啶-3-甲酰胺 [1,2,3]三唑并[1,5-a]吡啶-3-甲酰氯 N-羟基-7-氮杂苯并三氮唑 N-[5-[(1-甲基乙基)氨基]-7-(三氟甲基)[1,2,4]三唑并[1,5-a]吡啶-2-基]-3-吡啶甲酰胺 N,N-二乙基-7-硝基-1H-1,2,3-三唑并[4,5-c]吡啶-1-乙胺 GLPG-0634 中间体 ALK4/ALK5抑制剂 9-环戊基-7-乙基-3-(2-噻吩基)-6,9-二氢-5H-吡唑并[3,4-c][1,2,4]三唑并[4,3-A]吡啶 8-硝基[1,2,4]三唑并[4,3-a]吡啶 8-硝基[1,2,4]三唑并[1,5-a]吡啶 8-甲氧基-[1,2,4]噻唑并[1,5-a]吡啶-2-胺 8-甲氧基-5-碘-[1,2,4]噻唑并[1,5-a]吡啶-2-胺 8-甲基-[1,2,4]三唑并[1,5-A]吡啶 8-甲基-1,2,4噻唑并1,5-a吡啶-2-胺 8-溴2-甲基-[1,2,4]噻唑并[1,5-a]吡啶 8-溴-[1,2,4]噻唑并[1,5-a]吡啶-2-胺 8-溴-[1,2,4]三氮唑并[4,3-A]吡啶 8-溴-[1,2,4]三唑并[1,5-A]吡啶 8-溴-[1,2,4]三唑[4,3-a]吡啶-6-羧酸 8-溴-6-氯-2-甲基-[1,2,4]噻唑并[1,5-a]吡啶